Researchers in Australia showed a novel selection pathway for multifocal intraocular lenses (mfIOLs) for cataract patients was cost-effective, with patients achieving excellent vision and self-reported outcomes.
Writing in Clinical Ophthalmology, researchers said mfIOLs are not readily available in Australia’s public sector, due to the complexity of both patient selection and trainee experience with mfIOLs. To address this, they developed a patient-selection pathway implemented by a senior trainee. Twenty-seven patients (54 eyes) underwent cataract surgery with mfIOL implantation at Sydney’s Westmead Hospital, with spectacle independence subsequently achieved by 85% at distance, 81% at intermediate and 59% at near vision, said researchers. Patient satisfaction via the Catquest-9SF questionnaire and Near Visual Acuity Questionnaire yielded >85% and 100% scores, respectively.
The cost difference between bilateral monofocal and mfIOLs was found to be comparable to a pair of spectacles, with the projected annual cost to the health system for a 5%–10% eligibility rate being AU$1.1–2.3 million (NZ$1.21–2.53m), said researchers. “There are several funding models that can be applied to support equitable access and improved visual outcomes with mfIOLs within the government-funded health system,” they said.
